Facebook Pixel

Biologics for Psoriasis: What to Consider

By Anonymous
Rate This
Biologics for Psoriasis iStock

Psoriasis is a common chronic immune disease that causes skin cells to grow quickly. The fast growth can lead to scaly, itchy, dry, and red skin patches. More than 7.5 million people in the United States have psoriasis.

There are several treatment options for psoriasis, including topical treatments, prescription drugs, and phototherapy. If you have moderate to severe psoriasis and your current treatment isn't working, it may be time to think about a biologic.

Keep reading to find out more about this newer class of drugs.

Why are biologics a good option for psoriasis treatment?

Biologics are target-specific drugs that act by blocking certain inflammatory cytokines. Unlike other drugs that are derived from plants or chemicals, biologics are made from sugars, proteins, or nucleic acids. They may also be made from human, animal, or microorganism cells and tissues.

Biologics are considered to be both safe and effective.

How do biologics work?

Biologics used to treat psoriasis work by blocking certain inflammatory cytokines produced by specific pathways that cause psoriasis. Biologics target cytokines produced by two main pathways: Th1 and TH17.

Th1 mechanism

Some biologics target cytokines produced by T-helper cells (T-cells), which are involved in psoriasis.

Read more in Psoriasis Resources
  • Psoriasis. (2015). Retrieved from https://www.aad.org/media-resources/stats-and-facts/conditions/psoriasis
  • Cai, Y., Fleming, C., & Yan, J. (2012). New insights of T cells in the pathogenesis of psoriasis. Cellular & Molecular Immunology, 9(4), 302ñ309. Retrieved from http://www.nature.com/cmi/journal/v9/n4/full/cmi201215a.html
  • Callis Duffin, K., Yeung, H., Takeshita, J., Krueger, G. G., Robertson, A. D., Troxel, A. B., Ö Gelfand, J. M. (2014, March). Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practice. British Journal of Dermatology, 170(3), 672ñ680. Retrieved from http://onlinelibrary.wiley.com/doi/10.1111/bjd.12745/abstract 
  • Lewis, B. J., Rajpara, S., Haggart, A. M., Wilson, H. M., Barker, R. N., & Ormerod, A. D. (2013, July). Predominance of activated, clonally expanded T helper type 17 cells within the CD4+T cell population in psoriatic lesions. Clinical & Experimental Immunology, 173(1), 38ñ46. Retrieved from http://onlinelibrary.wiley.com/doi/10.1111/cei.12086/abstract
  • * Mease, P. J., McInnes, I. B., Kirkham, B., Kavanaugh, A., Rahman, P., van der Heijde, D., Ö Mpofu, S. (2015). Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. New England Journal of Medicine, 373(14), 1329ñ1339. Retrieved from http://www.nejm.org/doi/full/10.1056/NEJMoa1412679
  • Noda, S., Krueger, J. G., & Guttman-Yassky, E. (2014, November 17). The translational revolution and use of biologics in patients with inflammatory skin diseases. Journal of Allergy and Clinical Immunology, 135(2), 324ñ336. Retrieved from http://www.jacionline.org/article/S0091-6749(14)01669-8/abstract
  • Feely, M.A., Smith, B.L., & Weinberg, J.M. (2015, May). Novel psoriasis therapies and patient outcomes, part 2: biologic treatments?: cutis: cutaneous medicine for the practitioner. Cutis, 95(5), 282-290. Retrieved from http://www.cutis.com/the-publication/past-issues-single-view/novel-psoriasis-therapies-and-patient-outcomes-part-2-biologic-treatments/98d6e144e5a4d6d1be15f9de4efa53fd.html
  • Papoutsaki, M. & Antoniou, C. (2015). Biologic agents for psoriasis. European Handbook of Dermatological Treatments, 1411ñ1420. Retrieved from http://link.springer.com/chapter/10.1007%2F978-3-662-45139-7_137
  • Pariser D.M., Bagel J., Gelfand J.M., Korman, N.J., Ritchlin, C.T., Strober, B.E., Ö Van Voorhees, A.S. (2007, February). National psoriasis foundation clinical consensus on disease severity. Archives of Dermatology, 143(2), 239ñ242. Retrieved from http://archderm.jamanetwork.com/article.aspx?articleid=411159
  • Rachakonda, T. D., Schupp, C. W., & Armstrong, A. W. (2014, January 6). Psoriasis prevalence among adults in the United States. Journal of the American Academy of Dermatology, 70(3), 512ñ516. Retrieved from http://www.jaad.org/article/S0190-9622(13)01268-1/abstract
  • What is a biological product? (2015, August 20). Retrieved from http://www.fda.gov/AboutFDA/Transparency/Basics/ucm194516.htm

Psoriasis Resources

5 Ways to Stay Warm This Winter Without Agitating Your Psoriasis

5 Ways to Stay Warm This Winter Without Agitating Your Psoriasis

10 Ways to Treat Psoriasis at Home

10 Ways to Treat Psoriasis at Home

Why Your Psoriasis Treatment Is Not Working

Why Your Psoriasis Treatment Is Not Working

What's Your Psoriasis Severity?

What's Your Psoriasis Severity?

All in Psoriasis Resources

Add a CommentComments

There are no comments yet. Be the first one and get the conversation started!

Enter the characters shown in the image.
By submitting this form, you agree to EmpowHER's terms of service and privacy policy

We value and respect our HERWriters' experiences, but everyone is different. Many of our writers are speaking from personal experience, and what's worked for them may not work for you. Their articles are not a substitute for medical advice, although we hope you can gain knowledge from their insight.